Biotechnology is supported by investors.

, ,
Integral service around a transaction
BY : Diego GutiérrezApril Fri, 2016
Investment in biotechnology is booming. So far this year, in addition to the fact that several biotech companies such as Imbiomotion have received funding, Ysios, Spanish venture capital focused on the health sector, has raised capital for its fund and a new Caixa Impulse call has been opened.


New Caixa Impulse call for applications  

Caixa Impulse is a programme developed by La Caixa Foundation, together with Caixa Capital Risc and international experts, to accompany and provide financial support for projects in the field of life sciences and health, proposed or presented by Spanish research centres that are owners or co-owners of protected assets or in the process of being protected.

The first edition was held last year and, as a result of its success, this year it will be held again but with a series of changes: the number of beneficiaries of the programme has been increased from 15 to 20; the amount of financial aid per project has been increased, which can reach 70,000 euros, and the period of accompaniment has been extended from 6 to 8 months.

This call, which has just opened in March, will be open until 15 July.

The projects submitted will enter a two-stage selection process: evaluation of the proposals by evaluators from the life and health sciences and the business world; and face-to-face interviews with a panel of European experts from different fields: pharmaceuticals, business schools, health and biotech companies.

Sodena invests in TedCas

TedCas is a technology company in the healthcare sector that has developed the TedCube plug&play solution, which revolutionises access to and management of medical information in operating theatres, offering surgeons autonomy in the use of their equipment during their operations. The equipment allows, by means of gesture control and voice commands, to manage different devices in the operating theatre, which translates into greater asepsis, time and cost savings and improved patient safety by preventing the focus of the surgeon's activity from being diverted.

Sodena, which had already invested in TedCas in 2013, has strengthened its participation in the company, leading a new round of funding, which exceeds €500,000. The following have also joined the operation as new partners Start Up Capital Navarre (a vehicle managed by Sodena and in which 23 companies and institutions in favour of entrepreneurship in Navarre participate), which is a financial partner with 2.19%, together with private investors, some of which belong to the network Grow+ (promoted by Orkestra-Basque Competitiveness Institute).

The main objective of the round is to boost its commercial activity and scale its business in Europe. To this end, TedCas will reinforce its current management team with the incorporation of high-level executives, all of them with extensive commercial and business development experience in the medical sector.

Ysios Capital adds new investors to its fund

The biotech venture capital firm has added new investors to its fund. YsiosBioFundIIincluding the Banco Sabadell and some pension funds.

Since its launch in 2014, Ysios has reached €80M and aims to reach €100M by the end of the year.

Ysios has participated in the largest financing rounds ever held in Spain, such as the one closed by Sanifit or Minoryx in 2015.

Ysios Capital's partners - Joël Jean-Mairet, former minister Cristina Garmendia, Karen Wagner, Julia Salaverria and Josep Lluís Sanfeliu - say that part of the good reception of the second fund is due to the success of the first. "The business plan has been fulfilled by 99.9%," they say. Ysios BioFund I is now in the divestment phase. For now it is reaping a seven-year return of 48% and a multiple of 2.8 times invested capital. "A good return in the sector is 15%," they say. The fund still holds eight active firms in its portfolio.

Other posts that may interest you

Inveready bets on biotechnology, invests in Cuantum and AB-biotics in less than a month

Investors lose their fear of investing in biotechnology

Spanish biotech companies go public

If you are looking for financing for your company, contact us. Abra-Invest has a team of experts in alternative financing at your disposal with extensive experience in the biotech sector. Call us on + 34 944240141 or fill in the contact form. 

The M&A Professionals

Meet our services



Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?